Weekly Digest – September 2026 Weekly Digest – September 2026 03 September 2026: HUTCHMED announces licensing agreement with GSK for KRAS-EGFR antibody conjugate cancer therapy HUTCHMED announced an exclusive licensing agreement with GSK for HMPL-A830, a first-in-class KRAS-EGFR antibody-targeted therapy […]
Weekly Digest – August 2026 Weekly Digest – August 2026 20 August 2026: Akiram Therapeutics and ITM signed a Lu-177 supply agreement to support AKIR001 development in Solid tumors Akiram Therapeutics and ITM Isotope Technologies Munich have signed an agreement […]
Weekly Digest – July 2026 Weekly Digest – July 2026 22 July 2026: Samsung Bioepis enters into a commercial license agreement with IntoCell for an ADC candidate Samsung Bioepis has entered into a commercial license agreement with IntoCell for SBE303, […]
Weekly Digest – July 2026 Weekly Digest – July 2026 13 July 2026: VERAXA Biotech and Ardigen collaborate to accelerate AI-enabled BiTAC pipeline development VERAXA Biotech has entered an AI-enabled drug discovery collaboration with Ardigen to accelerate the development of […]
Weekly Digest – July 2026 Weekly Digest – July 2026 15 July 2026: Protina partners with Onconic Therapeutics on next-generation cancer drugs Proteina and Onconic Therapeutics have entered a strategic collaboration to develop next-generation oncology therapies, combining Proteina’s antibody engineering […]
Weekly Digest – July 2026 Weekly Digest – July 2026 09 July 2026: RyboDyn partners with U.S department of war to advance AI-discovered ADC therapies for Lung cancer RyboDyn received a $1.3 million grant from the U.S. Department of War […]
Weekly Digest – June 2026 Weekly Digest – June 2026 22 June 2026: Lonza and InduPro announce licensing agreement to advance next-generation ADC therapeutics Lonza and InduPro have entered into a licensing agreement to advance next-generation antibody-drug conjugate therapeutics, providing […]
Weekly Digest – June 2026 Weekly Digest – June 2026 15 June 2026: Lonza grants Antharis exclusive license to develop dual-payload ADCs for GI cancers Antharis Therapeutics has entered into an exclusive, target-specific licensing agreement with Lonza to develop next-generation […]
Weekly Digest – June 2026 Weekly Digest – June 2026 09 June 2026: AmMax Bio licenses antibody-drug conjugate technology for Hematological cancers from Lonza AmMax Bio has entered into a licensing agreement with Lonza to access its clinically validated antibody-drug […]
Weekly Digest – June 2026 Weekly Digest – June 2026 08 June 2026: Johnson & Johnson to acquire Firefly Bio to expand oncology pipeline with degrader ADC platform Johnson & Johnson has entered into a definitive agreement to acquire Firefly […]
